Linker Information
General Information of This Linker
| Linker ID |
LIN0CQIVQ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Gly-Gln linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C9H14BrN3O5
|
|||||
| Isosmiles |
OC([C@H](CCC(N)=O)NC(C([H])NC(CBr)=O)=O)=O
|
|||||
| InChI |
InChI=1S/C9H14BrN3O5/c10-3-7(15)12-4-8(16)13-5(9(17)18)1-2-6(11)14/h5H,1-4H2,(H2,11,14)(H,12,15)(H,13,16)(H,17,18)/t5-/m0/s1
|
|||||
| InChIKey |
IMIWVKDAITUAHG-YFKPBYRVSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
324.131
|
Polar area
|
138.59
|
||
|
Complexity
|
316.9300119
|
xlogp Value
|
-1.6676
|
|||
|
Heavy Count
|
18
|
Rot Bonds
|
8
|
|||
|
Hbond acc
|
4
|
Hbond Donor
|
4
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
38283215 ADC 10 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.6 ug/mL
|
High TNF expression (TNF +++) | ||
| Method Description |
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.
Click to Show/Hide
|
||||
| In Vitro Model | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia | K562 cells (TNF) | CVCL_0004 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50 ug/mL | Negative TNF expression (TNF-) | ||
| Method Description |
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.
Click to Show/Hide
|
||||
| In Vitro Model | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia | K562 cells (wt) | CVCL_0004 | ||
References